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Abstract 
Background: In order to increase the bioavailability of hydrophilic unstable drugs like anthocyanins, we employed 
a polymer-based nanoparticles approach due to its unique properties such as high stability, improved bioavailabil-
ity and high water-soluble drug loading efficiency. Anthocyanins constitute a subfamily of flavonoids that possess 
anti-oxidative, anti-inflammatory and neuroprotective properties. However, anthocyanins are unstable because their 
phenolic hydroxyl groups are easily oxidized into quinones, causing a reduced biological activity. To overcome this 
drawback and improve the free radical scavenging capabilities of anthocyanins, in the current study we for the first 
time encapsulated the anthocyanins in biodegradable nanoparticle formulation based on poly (lactide-co-glycolide) 
(PLGA) and a stabilizer polyethylene glycol (PEG)-2000. The biological activity and neuroprotective effect of anthocya-
nin loaded nanoparticles (An-NPs) were investigated in SH-SY5Y cell lines.
Results: Morphological examination under transmission electron microscopy (TEM) showed the formation of 
smooth spherically shaped nanoparticles. The average particle size and zeta potential of An-NPs were in the range of 
120–165 nm and −12 mV respectively, with a low polydispersity index (0.4) and displayed a biphasic release profile 
in vitro. Anthocyanins encapsulation in PLGA@PEG nanoparticles (NPs) did not destroy its inherent properties and 
exhibit more potent neuroprotective properties. An-NPs were nontoxic to SH-SY5Y cells and increased their cell 
viability against Aβ1–42 by its free radical scavenging characteristics and abrogated ROS generation via the p38-MAPK/
JNK pathways accompanied by induction of endogenous nuclear factor erythroid 2-related factor 2 (Nrf2) and heme 
oxygenase 1 (HO-1). Comparative to native bulk anthocyanins, An-NPs effectively attenuated Alzheimer’s markers like 
APP (amyloid precursor protein), BACE-1 (beta-site amyloid precursor protein cleaving enzyme 1), neuroinflammatory 
markers such as p-NF-kB (phospho-nuclear factor kappa B), TNF-α (tumor necrosis factor) and iNOS (inducible nitric 
oxide synthase) and neuroapoptotic markers including Bax, Bcl2, and Caspase-3 protein expressions accompanied by 
neurodegeneration against Aβ1–42 in SH-SY5Y cell lines.
Conclusions: Overall, this data not only confirmed the therapeutic potential of anthocyanins in reducing AD pathol-
ogy but also offer an effective way to improve the efficiency of anthocyanins through the use of nanodrug delivery 
systems.
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Background
A variety of chemical drugs have discovered and developed 
over the past several decades, but a few problems such as 
fast elimination and denaturation or degradation are still 
remain to be determined [1]. Many attempts to solve these 
problems have been made by using high dose or multi-
treatment of the drugs. However, it could be a very dan-
gerous choice for efficient therapy, because if overdoses 
out of range of therapeutic windows are used [2] nonspe-
cific toxicity of drugs could be caused [3]. One approach to 
overcome these problems was the packaging of the drugs 
into a particulate carrier system, i.e. solid polymeric nano-
particles and lipidic systems such as oil-in-water (O/W) 
emulsions and the liposomes [4]. In general, high drug 
stability in drug delivery technology leads to enhance the 
bioavailability of drug [5]. Incorporation of the drug into 
a particulate carrier protects it against the outer stresses 
in vitro and in vivo [6] maintain long-term circulation [7] 
and design the delivery to target site [8]. Poly (lactic-co-
glycolic acid) (PLGA) is one of the most successfully used 
biodegradable polymers because its hydrolysis leads to 
metabolite monomers, lactic acid and glycolic acid. These 
two monomers are endogenous and easily metabolized 
by the body via the Krebs cycle; a minimal systemic tox-
icity is associated with the use of PLGA for drug delivery 
or biomaterial applications [9]. PLGA is approved by the 
US FDA and European Medicine Agency (EMA) in vari-
ous drug delivery systems in humans. The polymers are 
commercially available with different molecular weights 
and copolymer compositions. The degradation time can 
vary from several months to several years, depending on 
the molecular weight and copolymer [10, 11]. The forms of 
PLGA are usually identified by the monomers ratio used. 
For example, PLGA 50:50 identifies a copolymer whose 
composition is 50% lactic acid and 50% glycolic acid. Poly 
(lactic acid) (PLA) has also been used to a lesser extent 
than PLGA due to the lower degradation rate [12].
The surface modification of a polymer with nontoxic 
and blood compatible material is essential in order to 
avoid recognition by macrophages, to prolong blood cir-
culation time and sustained release of the encapsulated 
drugs [13, 14]. Poly (ethylene glycol) (PEG) is widely used 
as hydrophilic nontoxic segment in combination with 
hydrophobic biodegradable aliphatic polyesters [15–18]. 
Incorporation of a hydrophilic PEG group on the surface 
of nanoparticles was found to show resistance against 
opsonization and phagocytosis and showed prolonged 
residence time in blood compared to the nanoparticles 
prepared without PEG [15, 16, 18].
Alzheimer’s disease (AD) is the most common age-
related neurodegenerative disorder characterised by 
progressive learning and memory deficit. The amyloid 
hypothesis of AD postulates that β-amyloid (Aβ) deposition 
and neurotoxicity play a causative role in AD [19]. The Aβ1–
42 is neurotoxic both in  vitro and in  vivo model [20, 21]. 
Recent evidence suggests that the neurotoxic properties of 
Aβ are mediated by oxidative stress [22].
Importantly nuclear factor erythroid 2-related factor 
2 (Nrf2) is a key redox-regulated gene that has a critical 
role against oxidative stress, Nrf2 nuclear level decreased 
in the hippocampus of AD patients [23]. Nrf2 regulated 
the several endogenous redox-regulated enzymes such as 
heme oxygenase-1 (HO-1) and glutathione cysteine ligase 
modulatory subunit (GCLM). Notably, heme oxyge-
nase-1 (HO-1) is beneficial in various diseases, especially 
neurodegenerative diseases such as AD [24]. Recently, 
investigated that nuclear translocation of Nrf-2 increased 
the expression of HO-1 [25]. Elevated expression of 
Nrf-2 both in vitro and in vivo AD model decreased the 
Aβ-induced neurodegeneration and oxidative stress [26].
In AD brain, activation of the MAPK pathways has 
been demonstrated in neurons and dystrophic neurites: 
c-Jun N-terminal kinase (JNK) [27, 28] and p38 [29]. 
Inhibition of the JNK pathway significantly reduced 
the toxicity attributable to Aβ in both of the studies. 
Increased p38 activity has been reported after Aβ treat-
ment of microglia [30]. The downstream signal transduc-
tion of the P38 and JNK pathways has been described to 
activate a variety of transcription factors and generate 
different inflammatory mediators [31]. Furthermore, it 
has been described that JNK signaling induces activator 
protein (AP)-1-dependent BAX and caspase activation, 
which results in neuronal apoptosis [32].
Anthocyanins constitute a subfamily of flavonoids that 
possess antioxidative, anti-inflammatory, and antineuro-
degenerative properties [33, 34]. Anthocyanin extracted 
from berries can improve cognitive brain function and 
reduce age associated oxidative stress [35–37]. They 
have been shown to prevent learning and memory loss in 
estrogen-deficient rats [38].
In this study, we constructed anthocyanin loaded 
(PLGA@PEG) nanoparticle system to assess the suit-
ability of the nanoparticles as delivery vehicles for hydro-
philic drugs, and studied its release kinetics in vitro. The 
biological activity and neuroprotective effect of encapsu-
lated anthocyanin were investigated in SH-SY5Y cell cul-
tures, confirming the protection against Aβ1–42-induced 
neurotoxicity. An-NPs were more potent than native bulk 
anthocyanin and exhibit anti-amyloid, anti-oxidative and 
anti-inflammatory properties and are non-cytotoxic.
Results
Preparation and characterization of anthocyanins‑loaded 
nanoparticles (An‑NPs)
Anthocyanins loaded PLGA@PEG nanoparticles 
(An-NPs) were prepared by emulsification-solvent 
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evaporation technique. Morphological examination 
under transmission electron microscopy (TEM) showed 
the formation of smooth spherically shaped nanoparti-
cles with an average diameter of 120–165 nm (Fig. 1a). 
The mean particle size and zeta potential were measured 
by dynamic light scattering (DLS) and Electrophoretic 
light scattering (ELS) analysis, respectively. The mean 
diameter of the NPs as determined from DLS meas-
urement was 165  nm with a low polydispersity index 
(0.4), indicating the formation of almost monodispersed 
nanoparticles (Fig. 1b). This observation was supported 
by the result obtained from the morphological examina-
tion using TEM analysis (Fig. 1a). The zeta potential of 
the prepared NPs measured by ELS was −12 mV.
Determination of interaction between anthocyanin 
and PLGA‑PEG ‑NPs
The physical interaction between anthocyanin and NPs 
was determined by FT-IR (Fourier transform infrared 
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Fig. 1 Transmission electron microscopy and DLS observations of An-NPs and its beneficial effects against Aβ1–42-induced neurotoxicity; a TEM 
micrograph of An-NP (scale bar 0.5 µm). b DLS analysis for the particle size of An-NPs. c In vitro cytotoxicity of PLGA@PEG NPs, native anthocyanin 
and An-NPs incubated with normal SH-SY5Y cells. Cell viability was measured by MTT assay. Four different concentrations of the test samples were 
added to the cells and incubated for 24 h before adding the respective assay reagents. We have observed that the nanoparticles were highly bio-
compatible. d Shown is the cell viability (MTT assay) histogram. Aβ1–42 (5 µM) reduced cell viability while anthocyanins and An-NPs at three different 
concentrations (50, 100 and 200 µg/ml) increased the cell viability of SH-SY5Y cell lines. e Representative ROS assay histogram. Anthocyanins and 
An-NPs in all three different concentrations (50, 100 and 200 µg/ml) significantly reduced Aβ1–42-induced (5 μM) ROS production. e The ApoTox-Glo 
Triplex Assay was performed (Promega, Promega BioSciences, LLC., San Luis Obispo, CA, USA). Histogram showing, cell viability. f Cytotoxicity and (g) 
Caspase-3/7 assays. All the related experimental details are provided in the “Methods” section. All these assays were performed in triplicate (±SEM). 
*Significantly different from the control; #significantly different from Aβ1–42-treated group. Significance = **p < 0.01, #p < 0.05, ##p < 0.01
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and their precursors PLGA@PEG and anthocyanin were 
recorded to confirm the structural composition of the 
final product. Additional file 1: Figure S1 shows the typi-
cal FT-IR spectra of the free anthocyanin, PLGA@PEG 
NPs and An-NPs. In the spectrum, no characteristics 
peaks can be distinguished in the An-NPs in which the 
characteristics absorption peaks were masked by that of 
NPs.
Drug loading and in vitro drug release
Anthocyanin was employed as a model drug to evaluate 
the potential of polymeric NPs to encapsulate hydrophilic 
drugs. In order to study the bioavailability and controlled 
release of anthocyanin from PEGylated nanoparticles, 
the drug was encapsulated in the PLGA@PEG nanopar-
ticles and its release kinetics was studied in  vitro. This 
in  vitro release profile of anthocyanin loaded PLGA@
PEG nanoparticles in PBS at 37 °C is shown in Additional 
file 1: Figure S2. Anthocyanin was encapsulated with 60% 
efficiency in biodegradable nanoparticle formulation 
based on poly (lactide-co-glycolide) (PLGA) and a stabi-
lizer polyethylene glycol (PEG)-2000, showing a biphasic 
release profile in  vitro. All the PEGylated nanoparticles 
showed similar release profiles of initial burst release 
of drug from the nanoparticles followed by a sustained 
release [39]. Allen et al. [39] described that some amount 
of the drug may be absorbed on the surface of nanopar-
ticles or loosely bound to the inner polymer core, which 
was lost during the initial stage of incubation, suggesting 
an initial burst release of the drug. The strongly encap-
sulated drug in the core domains followed slow and sus-
tained release kinetics. On the other hand, almost all the 
free anthocyanin was released into the medium within 
3 h (data not shown here). This result indicates that the 
PLGA@PEG nanoparticles effectively extended the sys-
temic release of anthocyanin and can be used for the 
effective controlled delivery of hydrophilic drugs.
Beneficial effects of An‑NPs against Aβ1–42‑induced 
neurotoxicity in vitro
Cytotoxicity profile of the nanoparticles was first stud-
ied in human neuroblastoma SH-SY5Y cell line  using 
MTT assay. Four different concentrations of each of the 
test sample PLGA@PEG NPs, native anthocyanins and 
An-NPs were used for the studies. The respective assay 
reagents were added after incubating the cells and the 
nanoparticles for 24 h. From the results shown in Fig. 1c, 
it is concluded that An-NPs do not possess any signifi-
cant cytotoxic effect and the observed cell viability was 
in between 85 and 95% at all mentioned concentrations. 
This is because both PLGA and PEG polymers are FDA 
approved safe materials so, these nanoparticles might 
be promising drug carriers with little cytotoxicity. Addi-
tionally, the same viability assays were repeated for the 
cytotoxic nature of An-NPs either alone or against the 
Aβ1–42-induced cytotoxicity in SH-SY5Y cell line (Fig. 1c, 
d). The cells received Aβ1–42 (5  μM) alone and in com-
bination with three different concentrations (50, 100 and 
200  µg/ml) of anthocyanin/An-NPs. The cell viability 
histogram reveals that Aβ1–42 significantly induced cell 
death. However, An-NPs treatment against Aβ1–42 signifi-
cantly increased the viability (Fig. 1d). Similarly, all three 
different concentrations (50, 100 and 200 µg) completely 
inhibited Aβ1–42-induced ROS generation indicates that 
native anthocyanin and An-NPs are potent antioxidants 
(Fig. 1e). This also reveals that the antioxidant activity of 
An-NPs is more significant as compared to three differ-
ent concentrations of alone anthocyanins (Fig.  1e). Fur-
thermore, the ApoTox-Glo™ Triplex Assay (containing 
viability/cytotoxicity and caspase-3/7 assays) was con-
ducted to evaluate and compare the neuroprotective role 
of An-NPs against Aβ1–42 in vitro. Here in too, treatment 
with An-NPs significantly reduced the neurotoxic effects 
of Aβ1–42, thereby increasing cell viability and decreasing 
cytotoxicity and caspase-3/7 activation. Our results also 
determined more significant neuroprotective effects in 
case of An-NPs treatment compared with alone antho-
cyanins treated group (Fig. 1f–h).
The cellular uptake of rhodamine‑loaded NPs by SH‑SY5Y 
cells
The cellular uptake analyses experiment was conducted 
to evaluate the ability of SH-SY5Y cells to engulf NPs. In 
order to investigate the intracellular retention, rhoda-
mine-loaded NPs were supplemented in DMEM media 
to cultured cells incubated for 12  h. The microphoto-
graphs images shown in Fig.  2 reveal that rhodamine-
loaded NPs were efficiently engulfed and internalized by 
SH-SY5Y cells.
An‑NPs prevented Aβ1–42‑induced P38/JNK pathways 
activation in vitro
It is well established that Aβ deposition occurs in the 
development of AD [40]. Western blot analyses were per-
formed to determine the proteins expression level of AD 
markers like APP and BACE-1 in the Aβ1–42 treated SH-
SY5Y cells. The results showed that An-NPs treatment 
showed a significant reduction in the level of APP and 
BACE-1 compared to Aβ1–42 treated group (Fig. 3a).
To investigate the beneficial effect of An-NPs against 
Aβ1–42-induced activation of the P38/JNK pathway, we 
performed western blot. As the literature highlighted that 
the two important members of the MAPK family of pro-
teins such as P38-MAPK and c-JNK mainly involved in 
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stress [41, 42], and their activation has been implicated in 
oxidative stress and further triggers inflammatory media-
tors such as TNF-α, interleukins, and iNOS [43, 44]. The 
western blot results shown in Fig.  3b indicate that An-
NPs treatment caused a significant reduction in p-P38 
and p-JNK protein expression compared with the Aβ1–42-
treated group. Moreover, An-NPs treatment significantly 
decreased the expression of BACE-1 and p-JNK com-
pared with the Aβ1–42-treated group and alone native 
anthocyanin as evaluated morphologically (Fig. 3c).
An‑NPs inhibited Aβ1–42‑activated NF‑κB and various 
inflammatory protein markers expression in vitro
Activation of the MAPK family of proteins induces the 
phosphorylation of other protein kinases and the genera-
tion of cytotoxic factors and proinflammatory cytokines 
[42]. To evaluate the effect of An-NPs on different 
inflammatory mediators, western blotting was performed 
to monitor the expression levels of phosphorylated-NF-
kB, TNF-α and iNOS proteins against Aβ1–42 in SH-SY5Y 
cell line. The results showed that Aβ1–42 supplementation 
significantly elevated the levels of these proteins in SH-
SY5Y cells compared with the control cells. In contrast 
treatment of An-NPs significantly inhibited the Aβ1–42-
induced increased expression of p-NF-kB, TNF-α and 
iNOS proteins (Fig. 3b).
An‑NPs treatment alleviated Aβ1–42‑induced oxidative 
stress and upregulated the endogenous antioxidant 
system in vitro
It has shown that Nrf-2 and its target anti-oxidant genes 
such as HO-1 has a critical role in the mechanism against 
oxidative stress and induced anti-oxidant mechanism 
that is assumed is beneficial in AD [45], while, Kanninen 
et  al. report states that nuclear translocation of Nrf-2 
increased the HO-1 expression [46]. The western blot 
results shown in Fig. 4a revealed that there are decreased 
levels of Nrf-2 and HO-1 proteins in the Aβ1–42-treated 
SH-SY5Y cells compared to the control group. On the 
other hand either anthocyanins alone (native) or in con-
jugation with nanoparticles (An-NPs) significantly upreg-
ulated the endogenous antioxidant genes such as Nrf-2 
and HO-1 proteins expression against Aβ1–42 treated 
cells.
There are several studies which demonstrate that 
8-oxoguanine (8-OxoG) is an oxidative stress marker 
and it is increased in the AD brain and APPswe/PS1del-
taE9 transgenic AD mouse model [47]. Therefore, we 
analysed the colocalization of oxidative stress marker 
i.e. 8-OxoG and Nrf-2 through immunofluorescence 
staining. The immunofluorescence results showed 
increased immunoreactivity of 8-OxoG and lower Nrf-2 
proteins expression in the Aβ1–42-treated SH-SY5Y cell 
Fig. 2 Microscopic study showing the cellular internalization of the rhodamin123-loaded PLGA@PEG NPs; Confocal laser scanning microscopy 
(CLSM) images of the SH-SY5Y cells treated with rhodamin123-loaded PLGA@PEG NPs for 12 h (scale bar 50 and 10 µm)
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line as compared to the untreated control cells. How-
ever, the cells received An-NPs has reduced immuno-
reactivity of 8-OxoG and increased the translocation of 
Nrf-2 proteins against Aβ1–42 in  vitro (Fig.  4b). These 
results clearly indicate that An-NPs have more signifi-
cant antioxidant activity compared to native anthocya-
nins (Fig. 4a, b).
An‑NPs prevented Aβ1–42‑induced apoptosis 
and neurodegeneration in vitro
Previous published literature has determined the pro-
apoptotic activity of Aβ1–42 and plays a critical role 
in neurodegeneration in AD [48]. The Bcl-2 family of 
proteins plays a crucial role in the intracellular apop-




Fig. 3 An-NPs attenuated Aβ pathology and prevents Aβ1–42-induced activation of P38/JNK Pathways. a Effect of An-NPs treatment on the 
expression of Alzheimer markers analyzed by Western Blot in Aβ1–42 treated SHSY-5Y cell line. Shown are representative Western Blots probed with 
antibodies of APP and BACE-1 in the Aβ1–42 treated SHSY-5Y cells. Data are the representative of three individual experiments (n = 3). The protein 
bands were quantified using sigma gel software. β-Actin was used to show equivalent amounts of protein loading. b Representative Western Blots 
of p-P38, p-JNK, p-NF-kB, TNF-α and iNOS in Aβ1–42-treated SH-SY5Y cells. Data are the representative of three individual experiments (n = 3). The 
protein bands were quantified using sigma gel software. β-Actin was used to show equivalent amounts of protein loading. c The double immuno-
fluorescence images of SH-SY5Y cells after Aβ1–42 and An-NPs treatment, showing p-JNK (green) and BACE-1 (red), proteins and their respective rela-
tive density histograms. The DAPI (blue) was used to stain the nucleus. All the experiments were performed in triplicate. The details are given in the 
"Methods" section. *Significantly different from the control; #significantly different from Aβ1–42-treated group. Significance = **p < 0.01, #p < 0.05, 
##p < 0.01
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regulated by this family of proteins involves antiapop-
totic proteins Bcl-2 and proapoptotic proteins Bax [49]. 
Our results showed that Aβ1–42 treatment significantly 
increase the expression of pro-apoptotic Bax proteins 
and decreases the expression of the anti-apoptotic pro-
teins Bcl-2 compared to the control cells. Interestingly, 
the An-NPs significantly reversed the expression level 
of Aβ1–42-induced Bax and Bcl-2 proteins. Similarly, 
western blot analysis was performed to determine the 
protein expression level of caspase-3 following Aβ1–42 
and An-NPs treatment. Our results showed that Aβ1–42 
administration significantly increases the protein level 
of caspase-3 in the SH-SY5Y cells. Consistent with 
other results, An-NPs treatment along with Aβ1–42 
showed a significant decrease in the level of caspase-3 
(Fig.  5a). For morphological assessment of Aβ1–42-
induced neuronal cell death, the antiapoptotic effects 
of An-NPs were examined using TUNEL staining in 
SH-SY5Y cells. The results showed that Aβ1–42 treat-
ment induced DNA damage and increased the number 
a b
Fig. 4 An-NPs treatment alleviated oxidative stress and upregulated Nrf-2 and its downstream targets genes HO-1 expressions. a Shown are repre-
sentative Western Blots probed with antibodies of Nrf2, and HO-1 in the Aβ1–42 treated SHSY-5Y cells. Data are the representative of three individual 
experiments (n = 3). The protein bands were quantified using sigma gel software. β-Actin was used to show equivalent amounts of protein loading. 
b The double immunofluorescence images of SH-SY5Y cells after Aβ1-42 and An-NPs treatment, showing 8-Oxo-G (green) and Nrf2 (red), proteins 
and their respective relative density histograms. The DAPI (blue) was used to stain the nucleus. All the experiments were performed in triplicate. 
The details are given in the “Methods” section. *Significantly different from the control; #significantly different from Aβ1–42-treated group. Signifi-
cance = **p < 0.01, #p < 0.05, ##p < 0.01
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of TUNEL positive cells compared with control group. 
Exposure to An-NPs following Aβ1–42 treatment signifi-
cantly reduced the number of TUNEL positive cells in 
SH-SY5Y cell lines showing enhanced neuroprotection 
compared to alone free anthocyanin (Fig. 5b).
Discussion
Nanotechnology is an emerging field that has been rec-
ognized to have the potential to make impacts on the 
detection, prevention and treatment of different human 
related diseases and disorders. For nearly last three dec-
ades, biodegradable PLGA nanoparticles have been 
extensively investigated as drug delivery systems for the 
treatment of several diseases [12]. In fact, nanoparticles 
can protect the encapsulated drug from degradation, 
release the drug in a controlled manner, improve its bio-
distribution and allow the drug to target the tissues [9]. 
In this study we developed anthocyanin loaded PLGA@
PEG nanoparticles. The main advantage of using PLGA-
NPs for drug delivery is their biodegradability, and there-
fore no surgery is needed to remove the implant after 
its function is no longer required [50, 51]. The aims 
of this work were to synthesize anthocyanins loaded 
biodegradable and biocompatible NPs for controlled 
delivery against Aβ1–42-induced intoxication and oxida-
tive stress in SH-SY5Y cell line using PLGA biodegrad-
able polymer as inner core and modifying the surface 
with nontoxic blood compatible material PEG to acts 
a b
Fig. 5 The beneficial effects of An-NPs against Aβ1–42-induced apoptosis and neurodegeneration; a effect of An-NPs treatment on the activation 
of apoptotic induced proteins analyzed by Western Blot in Aβ1–42 treated SH-SY5Y cell line. Induction of Bax, Bcl-2 and caspase-3 in Aβ1–42-treated 
SH-SY5Y cells were analyzed by Western Blot. Data are the representative of three individual experiments (n = 3). The protein bands were quantified 
using sigma gel software. β-Actin was used to show equivalent amounts of protein loading. b Representative photomicrographs of TUNEL and DAPI 
stained cells (magnification ×10 objective field, scale bar 50 µm) showing a high number of apoptotic neurons in Aβ1–42-treated group and com-
paratively low number of apoptotic neurons in Aβ plus An-NPs treated group. Data are the mean value (±SEM) for three independent experiments 
(n  =  3). *Significantly different from the control; #significantly different from Aβ1–42-treated group. Significance = **p < 0.01, ***P < 0.001, #p < 0.05, 
##p < 0.01, ###p < 0.001
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as outermost shell. Both PLGA and PEG are approved 
by the US FDA and European Medicine Agency (EMA) 
employed for various drug delivery systems in preclini-
cal and in clinical studies [52, 53]. These nanoparticles 
were prepared and fully characterized in terms of their 
particle size, surface charge, encapsulation efficiency 
and in  vitro anthocyanin release profile. Our prepared 
NPs were of the almost same size (in nanometer range), 
negative zeta potential and were suggested suitable for 
intracellular uptake as demonstrated by previously pub-
lished reports [54]. A close examination of the TEM 
micrograph at higher magnification and the image with 
lower resolution showed spherically circular shaped NPs 
(Fig. 1a). The outer region was presumed to be the hydro-
philic crystalline PEG segment, and the inner region was 
assigned to inner hydrophobic amorphous core [55]. The 
mean particle size of PLGA@PEG-anthocyanins nano-
particles was in the range of 120–165  nm, and the zeta 
potential around −12 mV, which is considered adequate 
to form stable dispersions. According to Lockman et al. 
[56], anionic charge on the nanoparticle supports entry 
through the blood–brain barrier when compared to the 
cationic nanoparticles. The repulsion among the high 
negatively charged NPs provides extra stability in aque-
ous solution [57]. Cell viability studies prove that An-NPs 
are not cytotoxic (Fig. 1c). The in vitro release of antho-
cyanins from An-NPs exhibits biphasic kinetics, which 
includes an initial burst release, caused by rapid drug 
diffusion from the surface of the nanospheres, followed 
by a sustained release that depends on drug diffusion 
and matrix erosion mechanisms. This biphasic profile 
was considered appropriate to obtain the desired effects. 
All the PEGylated nanoparticles showed similar release 
profiles of initial burst release of drug from the nano-
particles followed by a sustained release. The initial fast 
release of the drug from nanoparticles was suggested that 
some amount of the drug was absorbed on the surface 
or loosely bound to the inner polymer core and was lost 
during the initial stage of incubation while the strongly 
encapsulated drug in the core domains followed slow and 
sustained release kinetics [39].
The loading of the drugs in the form of nanocarriers 
makes an effective and site-specific delivery of the drug 
to its target site. Inside the cytoplasm, NPs remain longer 
and the drug is released slowly, resulting in a sustained 
therapeutic effect of the encapsulated agent [54]. The cel-
lular uptake of rhodamine-loaded NPs was monitored 
using CLSM. The PEGylated NPs loaded with rhodamine 
was taken up by the SH-SY5Y cells and the red fluores-
cence which is characteristics of rhodamine was visual-
ized clearly in the cytoplasm of the cells (Fig.  2). Some 
amount of fluorescence was also detected in the nucleus 
of the cell showing its intercalation in genomic DNA 
(Fig. 2). These results suggest that NPs were sufficiently 
internalized presumably via endocytosis like most of the 
other PEGylated drug conjugates [58]. The amorphous 
PEGylated NPs loaded with rhodamine was taken up by 
the prostate cancer DU145 cells [59].
Previous studies have shown that anthocyanins have 
antioxidant activities [60]. However, anthocyanins are 
unstable because their phenolic hydroxyl groups are eas-
ily oxidized into quinones, causing a reduced biological 
activity [61]. To overcome this drawback, anthocyanins 
are combined with macromolecules such as carbohy-
drates and proteins to increase their stability. Jiménez-
Aguilar et al. reported that anthocyanins combined with 
polysaccharides, which can significantly prolong antho-
cyanin degradation time, have increased stability [62]. 
In the present study we showed that Aβ1–42 treatment 
induced oxidative stress by generating ROS in SH-SY5Y 
cell line. While, ROS activate various molecular signal-
ing pathways. The free radical scavenging characteristics 
of An-NPs abrogated ROS production via alleviating the 
p38-MAPK/JNK signaling pathways. There can be multi-
ple points in signaling pathways that mediate such path-
way crosstalk when the components and their functional 
states of one pathway may affect the function of another 
pathway. In some cases, pathway crosstalk may be sus-
tained by single proteins through molecular switches 
provided by post-translational modifications. Namely, 
different phosphorylation events may lead to inhibi-
tion or activation of the target protein and consequently 
potentially inhibit one pathway and activate another. 
These findings are in line with previous literature which 
demonstrates that both P38-MAPK and c-JNK (mem-
bers of the MAPK family of proteins) mainly involved in 
stress conditions [41, 42]. Other studies also correlated 
the activation of these kinases with the induction of oxi-
dative stress and stimulation of pro-inflammatory mark-
ers such as TNF-α, interleukins, and iNOS [43, 44]. In the 
current study we have conducted immunofluorescence 
analysis to know about the correlation between BACE1 
and phosphorylated JNK after Aβ1–42 treatment. In con-
trast the An-NPs not only completely inhibited the acti-
vation and phosphorylation of JNK but also significantly 
reduced BACE1 expression in SH-SY5Y cells. Addition-
ally, we have shown that An-NPs stimulated the activa-
tion of endogenous antioxidant genes such as Nrf2 and 
HO-1 to cope with the oxidative stress induced by Aβ1–42 
in SH-SY5Y cell. The activation of the Nrf2/heme oxyge-
nase-1 (HO-1) axis was responsible for the prosurvival 
effect against oxidative stress. Moreover, it has been 
investigated that activated p-JNK lead to neuroinflamma-
tion and neurodegeneration [31, 32]. Our current find-
ings reveal that An-NPs scavenge ROS molecules and can 
also overcome the activation of kinases. In this regard we 
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could say that these An-NPs evidenced the presence of 
a cross talk between different stress kinases and endog-
enous antioxidant genes by a sustained drug release char-
acteristics. Interestingly, these An-NPs in comparative to 
free anthocyanins have shown more significant effects 
against Aβ1–42-induced oxidative stress, neuroinflamma-
tion and neurodegeneration in SH-SY5Y cell line.
The Aβ1–42 neurotoxicity is reported previously both 
in  vitro and in  vivo model [20, 21]. Oxidative stress is 
implicated in various neurodegenerative diseases includ-
ing AD. ROS induced oxidative stress is considered to be 
a critical mediator in the AD pathology [22]. The antho-
cyanins have antioxidant properties with a free radical 
scavenging activity [60]. Similarly, here we found the 
elevated ROS and oxidative stress level and activated 
immunofluorescence reactivity of 8-OxoG in the Aβ1–42-
treated SH-SY5Y cells. Interestingly, our natural anti-oxi-
dant anthocyanins and An-NPs attenuated the elevated 
ROS level and oxidative stress in the Aβ1–42-treated SH-
SY5Y cell lines.
Recently Zhang et  al. found that activation of Nrf2/
HO-1 signaling is protective against oxidative stress [63]. 
Numerous studies proposed that endogenous anti-oxi-
dant genes such as Nrf-2 and HO-1 activation produced 
neuroprotection in AD [45]. Consistently in our Aβ1–42-
treated SH-SY5Y cells the expression of Nrf-2 and HO-1 
were decreased. Treatment with An-NPs activates the 
expression of Nrf-2 and HO-1 and comparatively An-
NPs significantly increased the level of Nrf-2 and HO-1 
as compared to the Aβ1–42-treated group.
Our results also assured that An-NPs were also more 
active and potent than alone anthocyanin as it signifi-
cantly decreased the level of basic proteins associated 
with AD like APP and BACE-1 in Aβ1–42-treated SH-
SY5Y cells. It has been determined that pharmacologi-
cal inhibition of p38α-MAPK decreased the levels of the 
inflammatory cytokines TNF-α and IL-1β, and protected 
neuronal cells from synaptic protein loss and neurite 
degeneration [64]. Accordingly Wang et al. showed that 
JNK inhibition decreased the production of inflamma-
tory mediators, and inhibited the apoptotic pathway 
[65]. Although the exact neuroprotective mechanism 
of anthocyanins during Aβ1–42 mediated activation of 
the P38 and JNK pathways is not clear, our results indi-
cate that anthocyanins decreases the levels of p-P38 and 
p-JNK, which may decrease the production of inflam-
matory mediators such as p-NF-kB, TNF-α and iNOS. 
Hence we suggest that An-NPs are effective enough to 
behave as neuroprotective agent against Aβ1–42-induced 
neurotoxicity.
Studies have shown that p-JNK activation induces 
activator protein (AP)-1-dependent BAX and caspase 
activation, and as a result apoptosis will occur [32]. The 
result of western blot analysis showed that the induction, 
activation and cleavage of apoptotic markers were higher 
in An-NPs as compared to native anthocyanin. In addi-
tion, TUNEL and DAPI staining provided further sup-
porting evidence for An-NPs uptake and predominant 
amount of drug accumulation in the nucleus of Aβ1–42-
treated SH-SY5Y cells after internalization of NPs into 
the cytoplasm, which caused cellular DNA damage and 
the onset of apoptosis.
Figure  6 showing the schematic representation of 
intracellular uptake of anthocyanin loaded PEGylated 
NPs by SH-SY5Y cell via endocytosis. Inside the cellular 
cytoplasm, the endosome is broken down by lysosomal 
enzymes and the drug is released in the cytoplasm and 
reverts the Aβ1–42-induced Aβ pathology by abrogat-
ing ROS generation via the P38-MAPK/JNK pathways 
accompanied by induction of endogenous nuclear factor 
erythroid 2-related factor 2 (Nrf2) and heme oxygenase 
1 (HO-1).
Conclusions
To improve the bioavailability of hydrophilic drugs 
PLGA@PEG nanoparticles were investigated as the 
drug delivery system. These NPs contributed to improv-
ing stability of encapsulated drugs against the outer 
environmental changes and to controlling drug release. 
Therefore, we assumed that PLGA@PEG nanoparticles 
have a potential as drug carriers for unstably hydrophilic 
drugs. Overall we demonstrate that that anthocyanin-
loaded PLGA@PEG nanoparticles (An-NPs) formulation 
has enhanced cellular uptake and increased bioactivity 
in  vitro and were not cytotoxic even at high doses. In 
summary, it was observed from the cellular study that 
An-NPs targeted Aβ1–42 treated SH-SY5Y cells more 
efficiently than native anthocyanins thereby alleviated 
Aβ pathology with reduction of ROS-induced oxida-
tive stress through the activation of Nrf-2/HO-1 path-
way, and consequently regulated the important neuronal 
P38-MAPK/JNK signalling and prevents the apoptosis 
and neurodegeneration through suppression of Bax, cas-
pase-3 and TUNEL positive neuronal cells. Thus, it can 
be concluded that drug encapsulation in the PLGA@
PEG nanocarriers could accumulate more drugs at the 
target site for sustained period of time relative to free 
drug in solution. In conclusion comparative to native 
anthocyanins, An-NPs effectively attenuated Aβ-induced 
neurotoxicity in SH-SY5Y cells and showed significant 
anti-oxidant, anti-apoptotic, anti-inflammatory and anti-
Alzheimer’s effects and therefore we assume that An-NPs 
have more therapeutic potential to treat various neuro-
logical disorders like AD.
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Methods
Materials
Poly (lactide-co-glycolide) (PLGA)–PEG, sodium deoxy-
cholate, Aβ1–42 peptide and dichloromethane (DCM) 
were purchased from Sigma. All other chemicals used 
were of analytical grades. The anti-Bax, anti-Bcl-2, anti-
APP, anti-BACE-1, anti-Nrf2, anti-HO-1, anti-p-NF-
kB 65, anti-p-JNK, anti-TNFα, anti-iNOS, anti-p-P38, 
antibodies were purchased from Santa Cruz Biotech-
nology. Anti-caspase-3 and anti-actin antibodies were 
bought from Cell Signaling and anti-8-oxoguanine 
(anti-8-Oxo-G) were purchased from (Millipore, Bill-
erica, MA, USA). The secondary antibodies used in our 
experiments were goat anti-mouse IgG, goat anti-rabbit 
IgG and rabbit anti-goat IgG, purchased from Santa Cruz 
Biotechnology.
Preparation of anthocyanin loaded PLGA@PEG 
nanoparticles
Drug (Anthocyanin) loaded PLGA@PEG nanoparticles 
were prepared by way of a slightly modified emulsifi-
cation-solvent evaporation technique [66]. Briefly, the 
Fig. 6 Schematic representation of intracellular uptake of anthocyanin loaded PEGylated NPs by SH-SY5Y cell via endocytosis; inside the cellular 
cytoplasm, the endosome is broken down by lysosomal enzymes and the drug is released in the cytoplasm and reverts the Aβ1–42-induced Aβ 
pathology by abrogating ROS generation via the P38-MAPK/JNK pathways accompanied by induction of endogenous nuclear factor erythroid 
2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1)
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PLGA@PEG 100  mg and drug 10  mg were dissolved 
in 3  ml of DCM under continuous stirring. This mix-
ture was added to a 12  mM sodium deoxycholate solu-
tion (20  ml) and the mixture was probe sonicated at 
20% power for 10 min using a microtip probe sonicator 
D-12207. The emulsion formed was then gently stirred in 
a fume hood at room temperature until complete evapo-
ration of the organic phase achieved. The nanoparticles 
were purified by centrifugation at 12,000 rpm for 10 min 
and then washed with fresh water two times to remove 
the excessive emulsifier and untapped free drug. The 
nanoparticles suspension was freeze-dried in order to 
obtain a fine powder of the drug loaded nanoparticles. 
After centrifugation, the amount of anthocyanin in the 
supernatant was assayed by spectrophotometer (Hewlett 
Packard UV 8452A) at a wavelength of 520 nm. The drug 
encapsulation efficiency of PLGA-PEG nanoparticles was 
carried out as described previously [67]. Drug free nano-
particles were also prepared with the same method using 
single emulsion technique. For fluorescence-labeled NPs 
formulation, rhodamine-123 (0.5  mg/ml) was added to 
the inner aqueous phase and NPs were prepared using 
single emulsion–solvent evaporation method.
Encapsulation efficiency
The encapsulation efficiency of anthocyanin was deter-
mined by the spectrophotometric method. The entrap-
ment efficiency of anthocyanin in nanoparticles was 
found to be 60%. Briefly, 10 mg of anthocyanin nanopar-
ticles was dissolved in 2 ml of DCM and kept in an incu-
bator shaker with stirring for 30  min. The absorbance 
of the solution was measured at 520 nm. The amount of 
encapsulated anthocyanin was calculated from the stand-
ard curve drawn between varied amount of anthocyanin 
and absorbance, and all the measurements were carried 
out in triplicate. The encapsulation efficiency (EE) was 
determined from the following formula.
Physiochemical properties of nanoparticles
The nanoparticle surface morphology was examined 
using TEM (transmission electron microscopy) (Tec-
nai-12, 120 kV). A small quantity of aqueous solution of 
the lyophilized anthocyanin-loaded nanoparticles (1 mg/
ml) was placed on a TEM grid surface with a filter paper 
(Whatman No. 1). One drop of 10% uranyl acetate was 
added to the surface of the carbon-coated grid. After 
1  min of incubation, excess fluid was removed and the 
grid surface was air dried at room temperature. It was 
then loaded into the transmission electron microscope 
attached to a Gatan SC 1000 CCD camera.
EE% = weight of anthocyanin in nanoparticles/
weight of anthocyanin used for nanoparticle
preparation× 100
The zeta-potential and mean particle size of anthocy-
anin-loaded nanoparticles were measured by dynamic 
laser light scattering using a (ELS-Z, DLS-8000; Otsuka 
Electronics Co., Osaka, Japan). The nanoparticles were 
suspended in water at a concentration of 1  mg/ml. 
The mean particles’ size and charge were measured at 
25 ± 2 °C, by following settings in the Zetasizer: nominal 
5 mW He–Ne laser operating at 633 nm wavelength; vis-
cosity for water 0.89 cP, and refractive index of water 1.33. 
Zeta-potential values were presented as an average value 
of 30 runs, with triplicate measurements within each run. 
The mean particle size of the NPs was determined in trip-
licate, and the average values were calculated.
Fourier transform-infra red (FT-IR) spectra were 
observed to study the interaction of anthocyanin with 
NPs under vacuum on a VERTEX 80v (Bruker Optics) 
FT-IR spectrometer equipped with a DTGS (with KBr 
window) detector. Freeze-dried samples were mixed 
with KBr powder, ground at room temperature and by an 
agate mortar to be finally compressed into a thin tablet. 
The study was done in triplicate with the scanning range 
set between 400 and 4000 cm−1.
In vitro drug release
The measurement of anthocyanin release from the drug 
loaded nanoparticles in  vitro was carried out in a glass 
apparatus containing 50  ml of PBS (pH 7.4) at 37  °C as 
described previously [68]. In brief, 50  mg of the drug 
loaded nanoparticles was dispersed in 5  ml of PBS and 
placed into a cellulose membrane dialysis tube (molecu-
lar weight cutoff = 3000–3500 Da). The dialysis tube was 
then immersed in the release medium (50 ml) and incu-
bated in a shaker bath (100  rpm) at 37  °C. Aliquots of 
1 ml were periodically withdrawn from the solution. The 
volume of the solution was held constant by adding 1 ml 
of fresh buffer solution after each sampling to ensure sink 
condition. The amount of anthocyanin released in the 
medium was analyzed spectrometrically at 520 nm. The 
percent release of the anthocyanin was then plotted as a 
function of dialysis time.
For the control experiment, 5  mg of free anthocyanin 
was dissolved in DCM and poured into 5 ml of PBS and 
sonicated. The organic solvent was evaporated by stirring 
and most anthocyanin remained dissolved in the medium 
with little amount of suspended anthocyanin particles. 
All experiments were repeated in triplicate.
Cell culture and drug treatment
Amyloid-β1–42 (Sigma-Aldrich, St. Louis, MO, USA) was 
dissolved in sterile saline at concentration of 1  mg/ml 
to prepare stock solution. This solution was incubated 
at 37  °C for 4 days. The SH-SY5Y cells (purchased from 
Korean Cell Bank, South Korea) were maintained in a 
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solution DMEM, 10% fetal bovine serum (FBS) and anti-
biotics (penicillin and streptomycin), grown for 5  days 
and treated as follows: (1) Control: incubated in DMEM 
solution for 24  h; (2) Aβ1–42-treatment: incubated in 
DMEM solution containing Aβ1–42 (5  µM) for 24  h; (3) 
Aβ1–42  +  native anthocyanin treatment: incubated in 
DMEM solution containing Aβ1–42 (5  µM) for 12  h and 
then post incubated with native anthocyanin (200 µg/ml) 
for 12  h; (4) Aβ1–42  +  An-NPs treatment: incubated in 
DMEM solution containing Aβ1–42 (5  µM) for 12  h and 
then post incubated with An-NPs (200  µg/ml) for 12  h; 
All the cells were harvested at day 6 and used for the 
desired analysis.
MTT assay
First we checked the in vitro cytotoxicity of PLGA@PEG 
nanoparticles (without anthocyanin), native anthocya-
nin and anthocyanin loaded PLGA@PEG nanoparticles 
(An-NPs) in normal SH-SY5Y cells by 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay. Four different concentrations of each sample were 
tested in normal SH-SY5Y cell line. The cells were seeded 
in 96-well plates with 1  ×  104 cells/well and incubated 
with increasing concentrations of equivalent anthocyanin 
ranging from 50 to 200 μg/ml incubated at 37 °C for 24 h. 
The cells treated with the growth medium served as con-
trol. Following this, the cells were incubated with MTT 
solution for another 2–4  h at 37  °C. Subsequently, the 
medium in each well was replaced with DMSO. Finally, 
the absorbance of the solution in each well at 570  nm 
was measured using an ApoTox (Promega) instrument. 
All experiments were performed independently in trip-
licate. Further we confirmed the viability of the SH-
SY5Y against Aβ1–42 and was assessed by performing the 
MTT assay according to the manufacturer’s instructions 
(Sigma Aldrich). Briefly, the cells were cultured in 96-well 
plates at a density of 1 ×  104 cells per well in 100 µl of 
the Dulbecco’s modified Eagle’s medium (DMEM from 
Gibco, life technologies, USA). After 24  h, the medium 
was replaced with fresh medium containing Aβ1–42 
(5 µM), with three different concentrations (50, 100 and 
200  µg/ml) of anthocyanin or An-NPs in combination 
with Aβ1–42 (5  µM). The control cells received only the 
DMEM medium. The cytotoxicity of the cells was meas-
ured as described previously [69].
Oxidative stress (ROS) detection in vitro
The ROS assay in SH-SY5Y cells were conducted as 
described previously [70]. Briefly, the cells were cul-
tured in 96-well plates at a density of 1 ×  104 cells per 
well in 100 µl of the Dulbecco’s modified Eagle’s medium 
(DMEM from Gibco, life technologies, USA). After 24 h, 
the medium was replaced with fresh medium containing 
Aβ1–42 (5  µM), with three different concentrations (50, 
100 and 200  µg/ml) of anthocyanin or An-NPs in com-
bination with Aβ1–42 (5  µM). The control cells received 
only the DMEM medium. Following this, A 600-µM 
solution of DCFDA (20, 70-dichlorofluorescein diacetate) 
dissolved in DMSO/PBS was then added to each well, 
and the cells were incubated for 30 min. The plates were 
then read on an ApoTox-Glo (Promega) instrument at 
488/530 nm.
ApoTox‑Glo triplex assay
The ApoTox-Glo Triplex Assay (Promega) was performed 
to assess viability, cytotoxicity and caspase-3/7 activation 
within a single assay well. The assay consists of two parts: 
in the first part, the activities of two proteases, which are 
markers of cell viability and cytotoxicity, were measured 
simultaneously. SHSY-5Y cells (2 ×  104 cells) were cul-
tured in 96-well assay plates. Each well contained a final 
volume of 200 µl of DMEM containing 10% FBS and 1% 
penicillin/streptomycin. After 48 h of incubation at 37 °C 
in a humidified 5% CO2 incubator, the cells were treated 
with Aβ1–42, native anthocyanin and anthocyanin loaded 
PLGA@PEG nanoparticles as explained in the drug treat-
ment section. For the assay, 20  µl of the viability/cyto-
toxicity reagent containing both GF-AFC substrate and 
bis-AAF-R110 substrate was added to all the wells, briefly 
mixed via orbital shaking (500 rpm for 30 s) and incu-
bated for 1 h at 37 °C. The fluorescence was measured at 
two wavelengths: 400/505 nm (viability) and 485/520 nm 
(cytotoxicity). The GF-AFC substrate enters live cells and 
is cleaved by a live-cell protease to release AFC. The bis-
AAF-R110 substrate does not enter live cells but rather is 
cleaved by a dead-cell protease to release R110. The live-
cell protease activity is restricted to intact viable cells and 
is measured using a fluorogenic, cell-permeant peptide 
substrate [glycyl-phenylalanyl-aminofluo rocoumarin 
(GFAFC)]. A second fluorogenic, cell-impermeant pep-
tide substrate [bis-alanylalanylphenylalanyl-rhodamine 
110 (bis-AAF-R110)] was used to measure the activity of 
dead-cell proteases that are released from cells that have 
lost membrane integrity. The second part of the assay 
uses a luminogenic caspase-3 substrate, containing the 
tetrapeptide sequence DEVD, to measure caspase activ-
ity, luciferase activity and cell lysis. The caspase-Glo3/7 
reagent was added (100  ml) to all the wells and briefly 
mixed using orbital shaking (500 rpm for 30  s). After 
incubation for 30 min at room temperature, the lumines-
cence was measured to determine caspase activation.
Cellular uptake
The uptake of rhodamine-loaded PLGA@PEG NPs was 
studied in normal SH-SY5Y cell line using confocal laser 
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scanning microscopy (CLSM). For CLSM (Fluoview FV 
1000, Olympus, Japan) observation, freshly prepared 
rhodamine-123-loaded NPs suspension at concentra-
tion of 0.1  mg/ml was mixed with cell culture medium 
and added to the cells pre-cultured in 4-well cover glass 
chambers and incubated for 12 h. However, to the con-
trol group cells (cells not treated with rhodamine-loaded 
PLGA@PEG NPs), only the culture medium was changed 
and applied the same condition. Following incubation, 
the cells were washed three times with PBS and were 
fixed with 4% paraformaldehyde and again washed with 
PBS and incubated with DAPI for 5 min. The slides were 
then rinsed with PBS and glass cover slips were mounted 
on glass slides with mounting medium, and fluorescent 
images were captured with CLSM.
Western blot analysis
The western blot analysis were conducted as described 
previously [71]. Cells were harvested and then homog-
enized in 0.2  M PBS containing protease inhibitor 
cocktail. After centrifugation the respective protein sam-
ples were collected from each group and run through 
SDS-PAGE on 7–18% gels under reducing conditions. 
GangNam-STAIN (iNtRON Biotechnology) protein 
marker; 7–200  kDa was run in parallel for detection of 
the molecular weights of the proteins. The proteins were 
then transferred onto a polyvinylidene difluoride (PVDF) 
membrane and blocked in 5% skimmed milk. Immunob-
lotting were performed with respective primary antibod-
ies. Anti-actin antibody served as loading control. The 
membranes were then probed with a goat derived horse-
radish peroxidase-conjugated anti-rabbit IgG or anti-goat 
IgG or anti-mouse IgG secondary antibodies (Santa Cruz 
Biotechnology, CA, USA). The immunoreactions over the 
PVDF membrane were visualized using Ez West Lumi 
western blotting detection reagent (ATTO Corporation, 
Japan). The x-ray films were scanned and analyzed with 
computer based Sigma Gel software (Jandel Scientific, 
San Rafael, and Chicago, USA) to get the resultant band 
densities.
TUNEL assay
Terminal deoxynucleotidyl transferase (TdT)-mediated 
dUTP nick end labeling (TUNEL) staining was per-
formed according to the manufacturer recommenda-
tions to determine apoptotic cell death. In  situ cell 
death detection kit was purchased from Roche (Cat. No. 
11684809910). Confluent SH-SY5Y cell lines were treated 
as described in drug treatment section with blank media, 
Aβ1–42-treatment, Aβ1–42  +  anthocyanin and Aβ1–
42  +  An-NPs. To observe typical features of apoptosis, 
nuclear DNA was stained with terminal deoxynucleotidyl 
transferase (TdT)-mediated dUTP nick end-labeling 
(TUNEL) for 45  min (GenScript Corporation, USA). 
The cells were washed twice with PBS, and then coun-
terstained with 4,6-diamidino-2-phenylindole (DAPI) 
for 10 min (Molecular Probes, Eugene, OR, USA). Glass 
cover slips were mounted on glass slides with mount-
ing medium. TUNEL-positive (green) and DAPI (blue) 
staining patterns were acquired by use of a confocal 
laser scanning microscope (Fluoview FV 1000, Olympus, 
Japan).
Immunofluorescence staining
Briefly, the slides containing SH-SY5Y cells were 
washed twice for 10 min each in 0.01 M PBS and incu-
bated for 1 h in blocking solution containing 2% normal 
bovine serum (Santa Cruz Biotechnology), according to 
the antibody treatment, and 0.3% Triton X-100 in PBS. 
After blocking, the slides were incubated overnight at 
4  °C with anti-p-JNK, anti-BACE-1, and anti-Nrf2, 
(Santa Cruz Biotechnology) and mouse monoclonal 
anti-8-Oxo-G (Millipore) antibodies diluted 1:100 in 
blocking solution. Following this, the slides were incu-
bated for 2 h with the fluorescein isothiocyanate FITC/
TRITC-labeled secondary antibodies (1:50) (Santa Cruz 
Biotechnology). The slides were then counterstained 
with 40,6-diamidino-2-phenylindole (DAPI) for 10 min 
and mounted with the Prolong Anti-fade Reagent 
(Molecular Probe, Eugene, OR, USA). Staining images 
of the double immunofluorescence were examined 
using a confocal laser-scanning microscope (Flouview 
FV 1000, Olympus, Japan).
Data analysis
The Western blot bands were scanned and analyzed 
through densitometry using the Sigma Gel System 
(SPSS Inc., Chicago, IL). One-way analysis of vari-
ance (ANOVA) followed by a two-tailed independent 
Student’s t test were used for comparisons among the 
treated groups and the control. The Image-J software 
was used for immunohistological quantitative analy-
sis. The density values of the data were expressed as 
the means  ±  SEM of three independent experiments. 
p values less than 0.05 were considered to be statisti-
cally significant. *p < 0.05, **p < 0.01 and ***p < 0.001; 
and #p < 0.05, ##p < 0.01 and ###p < 0.001. *Significantly 
different from the control group; #significantly different 
from the Aβ1–42-treated group.
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